How to calculate the dose of chemotherapy

被引:187
作者
Gurney, H [1 ]
机构
[1] Westmead Hosp, Dept Med Oncol & Palliat Care, Westmead, NSW 2145, Australia
关键词
dose calculation; under-close; body surface area;
D O I
10.1038/sj.bjc.6600139
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Body surface area-dosing does not account for the complex processes of cytotoxic drug elimination, This leads to an unpredictable variation in effect. Overdosing is easily recognised but it is possible that unrecognised underdosing is more common and may occur In 30% or more of patients receiving standard regimen. Those patients who are inadvertently underdosed are at risk of a significantly reduced anticancer effect. Using published data, it can be calculated that there is an almost 20% relative reduction in survival for women receiving adjuvant chemotherapy for breast cancer as a result of unrecognised underdosing. Similarly, the cure rate of cisplatir-based chemotherapy for advanced testicular cancer may be reduced by as much as 10%. The inaccuracy of body surface area-dosing is more than an inconvenience and it is important that methods for more accurate dose calculation are determined, based on the known drug elimination processes for cytotoxic chemotherapy. Twelve rules for dose calculation of chemotherapy are given that can be used as a guideline until better dose-calculation methods become available. Consideration should be given to using fixed dose guidelines independent of body surface area and based on drug elimination capability, both as a starting dose and for dose adjustment, which may have accuracy, safety and financial advantages. (C) 2002 Cancer Research UK.
引用
收藏
页码:1297 / 1302
页数:6
相关论文
共 40 条
[21]   A PHASE-I/II STUDY OF DOSE AND ADMINISTRATION OF NONGLYCOSYLATED BACTERIALLY SYNTHESIZED G-M CSF IN CHEMOTHERAPY-INDUCED NEUTROPENIA IN PATIENTS WITH NON-HODGKINS-LYMPHOMAS [J].
HOVGAARD, D ;
NISSEN, NI .
LEUKEMIA & LYMPHOMA, 1992, 7 (03) :217-224
[22]   Regulation of multidrug resistance-associated protein 2 (ABCC2) by nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor [J].
Kast, HR ;
Goodwin, B ;
Tarr, PT ;
Jones, SA ;
Anisfeld, AM ;
Stoltz, CM ;
Tontonoz, P ;
Kliewer, S ;
Willson, TM ;
Edwards, PA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (04) :2908-2915
[23]   ANTICANCER DRUG RENAL TOXICITY AND ELIMINATION - DOSING GUIDELINES FOR ALTERED RENAL-FUNCTION [J].
KINTZEL, PE ;
DORR, RT .
CANCER TREATMENT REVIEWS, 1995, 21 (01) :33-64
[24]   Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression [J].
Kuehl, P ;
Zhang, J ;
Lin, Y ;
Lamba, J ;
Assem, M ;
Schuetz, J ;
Watkins, PB ;
Daly, A ;
Wrighton, SA ;
Hall, SD ;
Maurel, P ;
Relling, M ;
Brimer, C ;
Yasuda, K ;
Venkataramanan, R ;
Strom, S ;
Thummel, K ;
Boguski, MS ;
Schuetz, E .
NATURE GENETICS, 2001, 27 (04) :383-391
[25]   Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations [J].
Mathijssen, RHJ ;
Verweij, J ;
de Jonge, MJA ;
Nooter, K ;
Stoter, G ;
Sparreboom, A .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :81-87
[26]  
MCINTYRE OR, 1978, BLOOD S1, V52, P274
[27]   Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF [J].
Poikonen, P ;
Saarto, T ;
Lundin, J ;
Joensuu, H ;
Blomqvist, C .
BRITISH JOURNAL OF CANCER, 1999, 80 (11) :1763-1766
[28]   A RANDOMIZED STUDY COMPARING STANDARD DOSE CARBOPLATIN WITH CHLORAMBUCIL AND CARBOPLATIN IN ADVANCED OVARIAN-CANCER [J].
RANKIN, EM ;
MILL, L ;
KAYE, SB ;
ATKINSON, R ;
CASSIDY, L ;
CORDINER, J ;
CRUICKSHANK, D ;
DAVIS, J ;
DUNCAN, ID ;
FULLERTON, W ;
HABESHAW, T ;
KENNEDY, J ;
KENNEDY, R ;
KITCHENER, H ;
MACLEAN, A ;
PAUL, J ;
REED, N ;
SARKER, T ;
SOUKOP, M ;
SWAPP, GH ;
SYMONDS, RP .
BRITISH JOURNAL OF CANCER, 1992, 65 (02) :275-281
[29]   Body-surface area as a basis for dosing of anticancer agents: Science, myth, or habit? [J].
Ratain, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) :2297-2298
[30]   PHARMACOLOGICALLY BASED DOSING OF ETOPOSIDE - A MEANS OF SAFELY INCREASING DOSE INTENSITY [J].
RATAIN, MJ ;
MICK, R ;
SCHILSKY, RL ;
VOGELZANG, NJ ;
BEREZIN, F .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (08) :1480-1486